- Global Operation
- Contract Manufacturing
Zoledronic acid is a bisphosphonate and acts primarily on bone. It is an inhibitor of osteoclast-mediated bone resorption. The selective action of bisphosphonates on bone is based on their high affinity for mineralized bone. Intravenously administered zoledronic acid rapidly partitions to bone and localizes preferentially at sites of high bone turnover. The main molecular target of zoledronic acid in the osteoclast is the enzyme farnesyl pyrophosphate synthase. The relatively long duration of action of zoledronic acid is attributable to its high binding affinity to bone mineral.
i. Treatment and prevention of postmenopausal osteoporosis
ii. Treatment to increase bone mass in men with osteoporosis
iii. Treatment and prevention of glucocorticoid-induced osteoporosis
iv. Treatment of Paget’s disease of bone in men and women
Limitations of Use
Optimal duration of use has not been determined. For patients at low-risk for fracture, consider drug discontinuation after 3 to 5 years of use.
Zandra® Solution for IV Infusion 5 mg/100 mL: Each pack contains a single 100 mL glass bottle containing Zoledronic Acid INN 5 mg, one infusion set, one butterfly needle, one alcohol pad, one first aid bandage and one plastic hanger.